Loading...
We would love for you to become a part of our community. Join our Discord to connect with us and other members!
- Ticker
- MARI.VI
- Price
- -
- Stock movement up
- +0.70 (1.70%)
- Company name
- Marinomed Biotech AG
- Exchange
- (VI ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 63.20M
- Ent value
- 82.65M
- Price/Sales
- 5.45
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 38.00
- PEG
- -
- EPS growth
- 22.62%
- 1 year return
- -32.58%
- 3 year return
- -24.47%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
MARI.VI does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.45 |
| Price to Book | - |
| EV to Sales | 7.12 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.51M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 11.60M |
| Gross profit (TTM) | 2.03M |
| Operating income (TTM) | -5.02M |
| Net income (TTM) | -6.07M |
| EPS (TTM) | - |
| EPS (1y forward) | 1.10 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 17.46% |
| Operating margin (TTM) | -43.24% |
| Profit margin (TTM) | -52.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.40M |
| Net receivables | 3.18M |
| Total current assets | 10.03M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 17.83M |
| Accounts payable | 917.50K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 5.08M |
| Total liabilities | 24.85M |
| Shareholder's equity | -7.02M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.25M |
| Capital expenditures (TTM) | 140.70K |
| Free cash flow (TTM) | -5.39M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -34.03% |
| Return on Invested Capital | -48.61% |
| Cash Return on Invested Capital | -43.14% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| MARI.VI | S&P500 | |
| Current price drop from All-time high | -71.17% | -8.03% |
| Highest price drop | -77.31% | -56.47% |
| Date of highest drop | 17 May 2023 | 9 Mar 2009 |
| Avg drop from high | -27.60% | -11.12% |
| Avg time to new high | 21 days | 12 days |
| Max time to new high | 623 days | 1805 days |
COMPANY DETAILS
Marketcap
63.20M
Marketcap category
Small-cap
Description
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Employees
36
Website
Investor relations
-
SEC filings
CEO
Country
Austria
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found